eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2021
vol. 38
 
Share:
Share:
more
 
 
abstract:
Original paper

Analysis of the influence of adalimumab to the expression pattern of mRNA and protein of TGF-β1-3 in dermal fibroblast exposed to lipopolysaccharide

Michał Schweizer
1
,
Iwona Adwent
1
,
Beniamin O. Grabarek
1, 2
,
Dariusz Boroń
1, 3

1.
Department of Histology, Cytophysiology and Embryology, Faculty of Medicine, University of Technology, Katowice, Poland
2.
Department of Clinical Trials, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Krakow, Poland
3.
Department of Gynaecology and Obstetrics with Gynaecologic Oncology, Ludwik Rydygier Memorial Specialized Hospital, Krakow, Poland
Adv Dermatol Allergol 2021; XXXVIII (4): 597–602
Online publish date: 2020/04/06
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Psoriasis is a inflammatory illness, where incorrect expression of cytokines and bacteria lipopolysaccharide are observed. In the therapy of moderate to severe psoriasis anti-TNF drugs, i.e. adalimumab are used which have the influence for secreting another cytokines, such as transforming growth factor-β (TGF-β).

Aim
The goal of this study was to analyse the expression profile of mRNA TGF-β1-3 and proteins (TGF-β1 and TGF-β2) it codes in normal human dermal fibroblasts (NHDF) exposed to bacterial lipopolysaccharide (induction of inflammation) and adalimumab (anti-TNF drug).

Material and methods
NHDFs treated with bacterial lipopolysaccharide at a medium concentration of 1 µg/ml for 8 h, and then added to an adalimumab culture at a concentration of 8 µg/ml and continued exposure of the fibroblasts to it for 2, 8 and 24 h. The molecular analysis included microarray, RTqPCR and ELISA assays.

Results
Treating the skin fibroblast cells with LPS resulted in significant statistical changes in the expression of TGF-β1 (­) and TGF-β2 (Ż) in comparison to the control culture. Likewise, after adding adalimumab to the culture of NHDF treated previously with LPS, significant changes in the expression of TGF-β1 (­) and TGF-β2 (Ż) were noted in comparison to the control culture (p < 0.05). On the protein level it can be determined that LPS and adalimumab cause an increase in the concentration of TGF-β1 and a decrease in the expression of TGF-β2 in comparison to the control culture.

Conclusions
Blocking the signalling dependant on TNF-α using adalimumab causes an increase in the expression of TGF-β1 and a simultaneous decrease in the case of TGF-β2.

keywords:

transforming growth factor β1–3, adalimumab, LPS, inflammation

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe